Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A10940 | Pages: NA | Charts: NA | Tables: NA |
Endobronchial ultrasound (EBUS) is primarily used is diagnosis of the progression of lung cancer, its stages and assessment of further possible spread of the diseases to neighbouring body parts including lymph nodes. Endobronchial ultrasound (EBUS) technique has modernized over the time and enables the pulmonologists to sample tissues as well as fluid obtained from lungs and adjacent lymph nodes to visualize the structure surrounding the tracheobronchial tree. The EBUS and endobronchial ultrasound-assisted transbronchial needle aspiration (EBUS TBNA) are recently developed advanced techniques and show promising results in evaluation of pulmonary nodules, and diagnosis of lung infections. Additionally, endobronchial ultrasound biopsy has applications in identification of various diseases including tuberculosis and chronic pulmonary obstructive disorder that negatively impact the lungs and other respiratory organs. For instance, enlarged lymph nodes and abnormal development of masses in the chest and many others. Endobronchial ultrasound biopsy is a minimally invasive technique for collection of tissue samples, majorly from lungs.
COVID – 19 scenario analysis:
The factors including technological development in EBUS devices, consumer preference towards minimally invasive surgeries, growing prevalence of respiratory diseases like tuberculosis and high number of people suffering from lung cancer are driving the global endobronchial ultrasound biopsy market. While low cost of manufacturing in emerging countries is offering new growth avenues to the endobronchial ultrasound biopsy market for expansion in near future. Furthermore, rising geriatric population coupled with higher rates of lung infections and other respiratory ailments requiring endoscopic ultrasound procedures are the factors that fuel the growth of this market.
Certain studies in areas related to lung ailments and respiratory disorders concluded that endobronchial ultrasound is affordable and cost-effective in comparison with other therapies as it reduces the requirement for costly, invasive and highly morbid procedures like mediastinoscopy and thoracotomy. Additionally, EBUS offer better images that provides the physicians and pulmonologists in visualization of several complicated areas and enable more access to these difficult-to-reach areas which helps in efficient diagnosis and biopsy.
On the contrary, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an advanced technique, but it requires expertise and experience in implementing it effectively. Evidence-based procedures for training the pulmonologists in the area of EBUS-TBNA are necessary, however; as of now, no such accepted or standard techniques exist for assessing EBUS technical skills and competencies which would hamper the growth for this market. In addition to this, the high cost of these medical devices and dearth of proper reimbursement policies in emerging economies can potentially restrain the market.
Endobronchial ultrasound biopsy being a minimally invasive procedure is gaining popularity as an alternative to open surgeries that are invasive in nature, thereby shifting the patient preference towards minimally invasive surgeries owing to certain attributes such as minor incisions, lesser pain, tissue damage, prevention of surgical scars, rapid recovery and lesser stay at the healthcare facilities in comparison with invasive surgeries These techniques being increasingly used across the medical field as they benefit both the medical professionals and patients as they minimize the discomfort caused to patients due to open surgeries and mostly, avoid surgeries and physical harm. The advantages such as minor complications in rare cases, less pain and lower surgery costs pertaining to use of endobronchial ultrasound biopsy is likely to facilitate the market growth over the next few years.
Rising incidences of cancers and geriatric population are the factors that go hand-in-hand and are on rise since past few decades. The growth of cancers considering the current growth rate is estimated to have around 27.5 million new cancer cases annually by 2040 around the world. This represents an immense increase of 61.7% from the year 2018 and is further estimated to grow in males with an increasing rate of 67.6 comparatively higher than females estimated to increase at a rate of 55.3%. Additionally, lung cancer being 3rd major cause of cancer in the UK, resulting in 13% of new cases of cancer. Similarly in India, approximately 67,795 new reported cancer cases were seen in 2018. Due to high of cancer, and increasing population base suffering with lung cancer, the demand for endobronchial ultrasound biopsy procedures is expected to surge in the near future, thereby augment the market growth.
Key benefits of the report:
Questions answered in the Endobronchial ultrasound biopsy devices Market research report:
Key Market Segments
Key Market Players
Other Players